Azelastine and Mometasone

ApprovedSmall molecule

EEndeavor Health

Azelastine and Mometasone is one of 27 small molecule programs targeting Rhinitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

RhinitisActive, not recruiting

RhinitisApproved

Active, not recruiting

Competition

Competitive Landscape

44 competitors in Rhinitis

#DrugCompanyPhaseTrials

Flovent

GSK

Approved

1 2

Prevacid

Takeda

Approved

1 3

Aspercreme Warming

AAveritas Pharma, Inc.

Approved

4 4

Rhofade

KKenvue Brands

Approved

1 5

Xyzal

CChattem

Approved

1 6

Singulair

OOrganon and Co

Approved

1 7

Immunotherapy

Bristol-Myers Squibb

Approved

1 8

Diluent

Sanofi

Approved

1 9

Veramyst

GSK

Phase 3

1 10

Pulmicort

SSalix

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Post-ApprovalRecruiting

Rhinitis

NCT05626621

Clinical

Trials by Indication[1]

Rhinitis1 trial

Efficacy of Azelastine and Mometasone Irrigation in Comparison to Nasal Sprays in Patients With Chronic Rhinitis

Recruiting·EEndeavor Health·Phase 4·NCT05626621·81 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Azelastine and Mometasone. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Azelastine and Mometasone compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Azelastine and Mometasone. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Endeavor Health company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: EEndeavor Health

Azelastine and Mometasone

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Rhinitis1 trial

References

Drug Info

Quick Facts

Related News